

Khandan Keyomarsi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5000283/publications.pdf>

Version: 2024-02-01

153
papers

14,303
citations

53660

45
h-index

19136

118
g-index

156
all docs

156
docs citations

156
times ranked

15666
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. <i>Cell</i> , 1993, 75, 805-816. | 13.5 | 5,487 |
| 2 | Role of cell cycle in mediating sensitivity to radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 928-942. | 0.4 | 870 |
| 3 | Phosphorylation-Dependent Ubiquitination of Cyclin E by the SCFFbw7 Ubiquitin Ligase. <i>Science</i> , 2001, 294, 173-177. | 6.0 | 718 |
| 4 | Cyclin E and Survival in Patients with Breast Cancer. <i>New England Journal of Medicine</i> , 2002, 347, 1566-1575. | 13.9 | 522 |
| 5 | Redundant cyclin overexpression and gene amplification in breast cancer cells.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993, 90, 1112-1116. | 3.3 | 481 |
| 6 | Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 7797-7802. | 3.3 | 346 |
| 7 | Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. <i>Oncogene</i> , 2001, 20, 147-155. | 2.6 | 332 |
| 8 | An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990, 87, 8950-8954. | 3.3 | 263 |
| 9 | Atypical PKC α contributes to poor prognosis through loss of apical-basal polarity and Cyclin E overexpression in ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 12519-12524. | 3.3 | 231 |
| 10 | Transcriptional downregulation of gap-junction proteins blocks junctional communication in human mammary tumor cell lines.. <i>Journal of Cell Biology</i> , 1992, 118, 1213-1221. | 2.3 | 226 |
| 11 | CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. <i>Nature Communications</i> , 2017, 8, 15916. | 5.8 | 214 |
| 12 | Tumor-Specific Proteolytic Processing of Cyclin E Generates Hyperactive Lower-Molecular-Weight Forms. <i>Molecular and Cellular Biology</i> , 2001, 21, 6254-6269. | 1.1 | 179 |
| 13 | Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. <i>Oncogene</i> , 1998, 17, 2393-2402. | 2.6 | 177 |
| 14 | Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G0/G1 to S phase transition in normal and tumor cells. <i>Nucleic Acids Research</i> , 2000, 28, 2108-2113. | 6.5 | 170 |
| 15 | Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 2504-2508. | 3.3 | 142 |
| 16 | Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis. <i>Genome Research</i> , 2018, 28, 159-170. | 2.4 | 137 |
| 17 | Tumor-Specific Low Molecular Weight Forms of Cyclin E Induce Genomic Instability and Resistance to p21, p27, and Antiestrogens in Breast Cancer. <i>Cancer Research</i> , 2004, 64, 3198-3208. | 0.4 | 134 |
| 18 | Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 3654-3662. | 3.2 | 121 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Molecular Cloning, Characterization, and Regulation of the Human Mitochondrial Serine Hydroxymethyltransferase Gene. <i>Journal of Biological Chemistry</i> , 1997, 272, 1842-1848. | 1.6 | 117 |
| 20 | Cyclin E, a redundant cyclin in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 15215-15220. | 3.3 | 114 |
| 21 | The role of cyclin E in cell proliferation, development and cancer. , 1997, 3, 171-191. | | 107 |
| 22 | 2â€²-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. <i>Nature Communications</i> , 2014, 5, 3459. | 5.8 | 103 |
| 23 | Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2018, 78, 742-757. | 0.4 | 98 |
| 24 | Autophagy: A Novel Mechanism of Synergistic Cytotoxicity between Doxorubicin and Roscovitine in a Sarcoma Model. <i>Cancer Research</i> , 2008, 68, 7966-7974. | 0.4 | 95 |
| 25 | Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. <i>Targeted Oncology</i> , 2018, 13, 21-38. | 1.7 | 78 |
| 26 | Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3996-4013. | 3.2 | 77 |
| 27 | AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. <i>Molecular Cancer Research</i> , 2017, 15, 45-58. | 1.5 | 73 |
| 28 | Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. <i>Clinical Cancer Research</i> , 2018, 24, 6594-6610. | 3.2 | 70 |
| 29 | Synchronization of the cell cycle using Lovastatin. <i>Cell Cycle</i> , 2008, 7, 2434-2440. | 1.3 | 68 |
| 30 | Overexpression of the Low Molecular Weight Cyclin E in Transgenic Mice Induces Metastatic Mammary Carcinomas through the Disruption of the ARF-p53 Pathway. <i>Cancer Research</i> , 2007, 67, 7212-7222. | 0.4 | 64 |
| 31 | Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells. <i>Cancer Research</i> , 2016, 76, 2406-2418. | 0.4 | 64 |
| 32 | Cyclin E and Its Low Molecular Weight Forms in Human Cancer and as Targets for Cancer Therapy. <i>Cancer Biology and Therapy</i> , 2003, 2, 37-46. | 1.5 | 63 |
| 33 | PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness. <i>Nature Communications</i> , 2016, 7, 10633. | 5.8 | 63 |
| 34 | UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent. <i>Oncogene</i> , 1999, 18, 5691-5702. | 2.6 | 62 |
| 35 | Histone modification profiling in breast cancer cell lines highlights commonalities and differences among subtypes. <i>BMC Genomics</i> , 2018, 19, 150. | 1.2 | 62 |
| 36 | Cyclin E deregulation alters the biologic properties of ovarian cancer cells. <i>Oncogene</i> , 2004, 23, 2648-2657. | 2.6 | 58 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. <i>Investigational New Drugs</i> , 2015, 33, 890-894. | 1.2 | 58 |
| 38 | The Tumor-specific Hyperactive Forms of Cyclin E Are Resistant to Inhibition by p21 and p27. <i>Journal of Biological Chemistry</i> , 2005, 280, 15148-15157. | 1.6 | 57 |
| 39 | Cyclin E as a prognostic and predictive marker in breast cancer. <i>Seminars in Cancer Biology</i> , 2005, 15, 319-326. | 4.3 | 56 |
| 40 | Cdk2 is Required for Breast Cancer Mediated by the Low-Molecular-Weight Isoform of Cyclin E. <i>Cancer Research</i> , 2011, 71, 3377-3386. | 0.4 | 55 |
| 41 | A novel interaction between HER2/neu and cyclin E in breast cancer. <i>Oncogene</i> , 2010, 29, 3896-3907. | 2.6 | 54 |
| 42 | Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 593-607. | 1.9 | 54 |
| 43 | Low Molecular Weight Cyclin E Overexpression Shortens Mitosis, Leading to Chromosome Missegregation and Centrosome Amplification. <i>Cancer Research</i> , 2010, 70, 5074-5084. | 0.4 | 53 |
| 44 | Novel splice variants of cyclin E with altered substrate specificity. <i>Nucleic Acids Research</i> , 2000, 28, 101e-101. | 6.5 | 48 |
| 45 | Low-Molecular-Weight Cyclin E Can Bypass Letrozole-Induced G1 Arrest in Human Breast Cancer Cells and Tumors. <i>Clinical Cancer Research</i> , 2010, 16, 1179-1190. | 3.2 | 47 |
| 46 | Farnesyl and Geranylgeranyl Transferase Inhibitors Induce G1 Arrest by Targeting the Proteasome. <i>Cancer Research</i> , 2006, 66, 1040-1051. | 0.4 | 46 |
| 47 | Hbo1 Is a Cyclin E/CDK2 Substrate That Enriches Breast Cancer Stem-like Cells. <i>Cancer Research</i> , 2013, 73, 5556-5568. | 0.4 | 46 |
| 48 | Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2991-3002. | 3.2 | 46 |
| 49 | Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. <i>Cell Cycle</i> , 2009, 8, 1062-1068. | 1.3 | 45 |
| 50 | The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. <i>Cancer Research</i> , 2005, 65, 692-7. | 0.4 | 44 |
| 51 | Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 741-751. | 1.9 | 43 |
| 52 | Cytoplasmic Cyclin E and Phospho- γ -Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer. <i>American Journal of Pathology</i> , 2016, 186, 1900-1912. | 1.9 | 42 |
| 53 | Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R3. | 2.2 | 40 |
| 54 | Altered Subcellular Localization of Tumor-Specific Cyclin E Isoforms Affects Cyclin-Dependent Kinase 2 Complex Formation and Proteasomal Regulation. <i>Cancer Research</i> , 2009, 69, 2817-2825. | 0.4 | 39 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1751-1764. | 1.9 | 39 |
| 56 | Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. <i>Cancer Research</i> , 2018, 78, 5481-5491. | 0.4 | 39 |
| 57 | EV1 splice variants modulate functional responses in ovarian cancer cells. <i>Molecular Oncology</i> , 2013, 7, 647-668. | 2.1 | 38 |
| 58 | Indole-3-carbinol and its N-alkoxy derivatives preferentially target ER α -positive breast cancer cells. <i>Cell Cycle</i> , 2014, 13, 2587-2599. | 1.3 | 38 |
| 59 | DEAR1 Is a Dominant Regulator of Acinar Morphogenesis and an Independent Predictor of Local Recurrence-Free Survival in Early-Onset Breast Cancer. <i>PLoS Medicine</i> , 2009, 6, e1000068. | 3.9 | 37 |
| 60 | Activation of the Estrogen-Signaling Pathway by p21WAF1/CIP1 in Estrogen Receptor-Negative Breast Cancer Cells. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1403-1413. | 3.0 | 36 |
| 61 | The Low Molecular Weight Isoforms of Cyclin E Deregulate the Cell Cycle of Mammary Epithelial Cells. <i>Cell Cycle</i> , 2003, 2, 459-464. | 1.3 | 36 |
| 62 | LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients. <i>PLoS Genetics</i> , 2012, 8, e1002538. | 1.5 | 35 |
| 63 | Targeting low molecular weight cyclin E (LMW-E) in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 575-588. | 1.1 | 35 |
| 64 | Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. <i>Oncotarget</i> , 2017, 8, 14897-14911. | 0.8 | 35 |
| 65 | Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. <i>Cancer Biology and Therapy</i> , 2003, 2, S38-47. | 1.5 | 34 |
| 66 | Cyclin E Deregulation Impairs Mitotic Progression through Premature Activation of Cdc25C. <i>Cancer Research</i> , 2010, 70, 5085-5095. | 0.4 | 33 |
| 67 | Cyclin E deregulation is an early event in the development of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 651-659. | 1.1 | 32 |
| 68 | Activation of Cyclin-dependent Kinase 2 by Full Length and Low Molecular Weight Forms of Cyclin E in Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 12695-12705. | 1.6 | 31 |
| 69 | Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion. <i>Cell Cycle</i> , 2016, 15, 1579-1590. | 1.3 | 31 |
| 70 | Cyclin E is a better prognostic marker for breast cancer than cyclin D?. <i>Nature Medicine</i> , 1996, 2, 254-254. | 15.2 | 29 |
| 71 | The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase. <i>Oncogene</i> , 2015, 34, 3556-3567. | 2.6 | 29 |
| 72 | Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7288-7300. | 3.2 | 29 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Synthesis and Biological Activity of N.omega.-Hemiphthaloyl-.alpha.,.omega.-diaminoalkanoic Acid Analogs of Aminopterin and 3',5-Dichloroaminopterin. <i>Journal of Medicinal Chemistry</i> , 1994, 37, 2167-2174. | 2.9 | 27 |
| 74 | Anti-HER2 Antibody Trastuzumab Inhibits CDK2-Mediated NPAT and Histone H4 Expression via PI3K Pathway. <i>Cell Cycle</i> , 2006, 5, 1654-1661. | 1.3 | 26 |
| 75 | The Double-Stranded RNA-Activated Protein Kinase Mediates Radiation Resistance in Mouse Embryo Fibroblasts through Nuclear Factor κ B and Akt Activation. <i>Clinical Cancer Research</i> , 2007, 13, 6032-6039. | 3.2 | 26 |
| 76 | The Neutrophil Elastase Inhibitor Elafin Triggers Rb-Mediated Growth Arrest and Caspase-Dependent Apoptosis in Breast Cancer. <i>Cancer Research</i> , 2010, 70, 7125-7136. | 0.4 | 26 |
| 77 | Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. <i>Nature Medicine</i> , 2003, 9, 152-152. | 15.2 | 25 |
| 78 | Modification of cell proliferation with inhibitors. <i>Current Opinion in Cell Biology</i> , 1992, 4, 186-191. | 2.6 | 24 |
| 79 | Low-molecular-weight cyclin E: the missing link between biology and clinical outcome. <i>Breast Cancer Research</i> , 2004, 6, 188-91. | 2.2 | 24 |
| 80 | Deregulation of cyclin E meets dysfunction in p53: Closing the escape hatch on breast cancer. <i>Journal of Cellular Physiology</i> , 2006, 209, 686-694. | 2.0 | 23 |
| 81 | Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. <i>Breast Cancer Research</i> , 2014, 16, 3417. | 2.2 | 21 |
| 82 | PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 607-631. | 1.9 | 20 |
| 83 | The Biphasic Induction of p21 and p27 in Breast Cancer Cells by Modulators of cAMP Is Posttranscriptionally Regulated and Independent of the PKA Pathway. <i>Experimental Cell Research</i> , 1999, 252, 211-223. | 1.2 | 19 |
| 84 | Differential Regulation of Elafin in Normal and Tumor-Derived Mammary Epithelial Cells Is Mediated by CCAAT/Enhancer Binding Protein β . <i>Cancer Research</i> , 2007, 67, 11272-11283. | 0.4 | 19 |
| 85 | Absence of pRb facilitates E2F1-induced apoptosis in breast cancer cells. <i>Cell Cycle</i> , 2010, 9, 1122-1130. | 1.3 | 19 |
| 86 | The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. <i>Cell Cycle</i> , 2003, 2, 461-6. | 1.3 | 19 |
| 87 | Expression of an estrogen receptor alpha variant protein in cell lines and tumors. <i>Molecular and Cellular Endocrinology</i> , 2000, 162, 167-180. | 1.6 | 18 |
| 88 | Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer. <i>Cell Cycle</i> , 2012, 11, 1468-1476. | 1.3 | 18 |
| 89 | PKC δ promotes ovarian tumor progression through deregulation of cyclin E. <i>Oncogene</i> , 2016, 35, 2428-2440. | 2.6 | 17 |
| 90 | Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agents. <i>Progress in Cell Cycle Research</i> , 2003, 5, 527-32. | 0.9 | 17 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 115-126. | 1.8 | 16 |
| 92 | Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration. Cancers, 2021, 13, 1656. | 1.7 | 16 |
| 93 | Palbociclib plus endocrine therapy significantly enhances overall survival of HR^+ / HER2^{\sim} metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study. International Journal of Cancer, 2022, 150, 2025-2037. | 2.3 | 16 |
| 94 | The Differential Staurosporine-Mediated G1 Arrest in Normal versus Tumor Cells Is Dependent on the Retinoblastoma Protein. Cancer Research, 2006, 66, 9744-9753. | 0.4 | 15 |
| 95 | Cyclin E-Associated Kinase Activity Predicts Response to Platinum-Based Chemotherapy. Clinical Cancer Research, 2007, 13, 4800-4806. | 3.2 | 15 |
| 96 | Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. Journal of Cancer, 2017, 8, 2004-2009. | 1.2 | 14 |
| 97 | How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?. Cancer, 2015, 121, 806-816. | 2.0 | 13 |
| 98 | Breaking the cycle: An insight into the role of ERKs in eukaryotic cell cycles. Journal of Carcinogenesis, 2011, 10, 25. | 2.5 | 12 |
| 99 | Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer. British Journal of Cancer, 2020, 122, 812-822. | 2.9 | 11 |
| 100 | Post-translational modification and stability of low molecular weight cyclin E. Oncogene, 2009, 28, 3167-3176. | 2.6 | 10 |
| 101 | Staurosporine is chemoprotective by inducing G 1 arrest in a Chk1- and pRb-dependent manner. Carcinogenesis, 2013, 34, 2244-2252. | 1.3 | 10 |
| 102 | [47] Preparation of (6S)-5-formyltetrahydrofolate labeled at high specific activity with ^{14}C and ^3H . Methods in Enzymology, 1986, 122, 309-312. | 0.4 | 9 |
| 103 | MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells. Cancer Gene Therapy, 2011, 18, 510-519. | 2.2 | 8 |
| 104 | Progression through the Cell Cycle: An Overview. The American Review of Respiratory Disease, 1990, 142, S3-S6. | 2.9 | 6 |
| 105 | Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. Annals of Surgery, 2021, 274, e150-e159. | 2.1 | 5 |
| 106 | Cell Cycle Deregulation in Breast Cancer: Insurmountable Chemoresistance or Achilles' Heel?. Advances in Experimental Medicine and Biology, 2007, 608, 52-69. | 0.8 | 5 |
| 107 | Synchronization of mammalian cells by Lovastatin. Cytotechnology, 1996, 18, 109-114. | 0.7 | 4 |
| 108 | Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells. Cell Biology and Toxicology, 2011, 27, 123-131. | 2.4 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 109 | Abstract PD2-05: Differential mechanisms of acquired resistance to abemaciclib versus palbociclib reveal novel therapeutic strategies for CDK4/6 therapy-resistant breast cancers. <i>Cancer Research</i> , 2020, 80, PD2-05-PD2-05. | 0.4 | 4 |
| 110 | Cyclin E in Breast Cancer. <i>New England Journal of Medicine</i> , 2003, 348, 1063-1064. | 13.9 | 3 |
| 111 | Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age. <i>Cancers</i> , 2020, 12, 712. | 1.7 | 3 |
| 112 | Abstract 2060: Characterizing acquired resistance to palbociclib in breast cancer. <i>Cancer Research</i> , 2017, 77, 2060-2060. | 0.4 | 3 |
| 113 | LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers. <i>Oncogenesis</i> , 2021, 10, 40. | 2.1 | 2 |
| 114 | A phase 1 study of dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 163-163. | 0.8 | 2 |
| 115 | Leveraging MYC as a therapeutic treatment option for TNBC. <i>Oncoscience</i> , 2018, 5, 137-139. | 0.9 | 2 |
| 116 | CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2. <i>Cancer Research</i> , 2022, 82, 3088-3101. | 0.4 | 2 |
| 117 | Toxicity of Radiation Therapy Given Concomitantly with Palbociclib for Metastatic Breast Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, E60. | 0.4 | 1 |
| 118 | Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC). <i>Journal of Clinical Oncology</i> , 2021, 39, 1067-1067. | 0.8 | 1 |
| 119 | Exploiting Cell Cycle Pathways in Cancer Therapy: New (and Old) Targets and Potential Strategies. <i>Cancer Drug Discovery and Development</i> , 2014, , 337-372. | 0.2 | 1 |
| 120 | Abstract 1783: Pharmacological inhibition of CDK4/6 induces G1 arrest, autophagy and senescence in ER+ breast cancer. , 2015, , . | | 1 |
| 121 | Abstract 2466: Elafin, a serine protease inhibitor, is deregulated during breast cancer progression. , 2012, , . | | 1 |
| 122 | Abstract B27: CDK inhibition impairs homologous recombination and induces PARP inhibitor sensitivity via loss of c-myc expression in TNBC. , 2015, , . | | 1 |
| 123 | Relationships of cyclin E with clinical outcome and biomarkers in older women with early operable primary breast cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, e12031-e12031. | 0.8 | 1 |
| 124 | Abstract P2-05-04: Low molecular weight cyclin E facilitates replication stress tolerance in breast cancer development. , 2020, , . | | 1 |
| 125 | Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. <i>Cancer</i> , 2005, 104, 1779-1780. | 2.0 | 0 |
| 126 | A novel MCM-2 fragment with potential biological function in senescence. <i>Cell Cycle</i> , 2008, 7, 3479-3480. | 1.3 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Understanding the Biology of Cancer. , 0, , 101-122. | | 0 |
| 128 | Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Breast Diseases, 2011, 22, 266-267. | 0.0 | 0 |
| 129 | Targeting the Cell Cycle in Breast Cancer. Breast Diseases, 2016, 27, 256-260. | 0.0 | 0 |
| 130 | Arthur B. Pardee: In Memoriam (1921â€“2019). Cancer Research, 2019, 79, 2089-2090. | 0.4 | 0 |
| 131 | Biomarkers in Neoadjuvant Trials. Cancer Treatment and Research, 2009, 147, 1-36. | 0.2 | 0 |
| 132 | Abstract 3057: The serine protease inhibitor, elafin, exhibits novel tumor suppressor functions in the context of breast cancer. , 2010, , . | | 0 |
| 133 | Abstract 3283: Conditional Low-molecular-weight (LMW) cyclin E-induced mammary tumorigenesis. , 2012, , . | | 0 |
| 134 | Abstract 1327: Targeting the RB-pathway in sarcoma: Utility of CDK4/6 inhibitors. , 2014, , . | | 0 |
| 135 | Abstract P6-03-09: Targeting the c-myc/E2F1 pathway in TNBC promotes a DNA damage dependent synthetic lethality. , 2015, , . | | 0 |
| 136 | Abstract P5-05-05: Low molecular weight cyclin E regulates response to aromatase inhibitors in post-menopausal breast cancer patients. , 2015, , . | | 0 |
| 137 | Abstract P5-08-02: Inhibition of CDK4/6 induces senescence and autophagy in ER positive breast cancers. , 2015, , . | | 0 |
| 138 | Abstract 3772: Cyclin E as a prognostic marker and predictor of response to neoadjuvant chemotherapy and adjuvant hormonal therapy in patients with stage II-III breast cancer. , 2015, , . | | 0 |
| 139 | Abstract 3091: Targeting low molecular weight (LMW) cyclin E-Cdk2 pathway for the prevention of breast cancer. , 2015, , . | | 0 |
| 140 | Abstract 3579: Identification of biomarkers of AXL-mediated drug resistance in head and neck squamous cell carcinoma. , 2015, , . | | 0 |
| 141 | Abstract 1422: Neutrophil Elastase plays a key role in epithelial-mesenchymal transition and metastasis in triple-negative breast cancers. , 2015, , . | | 0 |
| 142 | Abstract PR06: Analysis of enhancer transcription reveals novel gene regulatory networks in breast cancer. , 2016, , . | | 0 |
| 143 | Abstract 2989: An Intact G1/S checkpoint determines response to CDK4/6 inhibitor in breast cancer. , 2016, , . | | 0 |
| 144 | Abstract 2338: CDK4/6 and autophagy inhibitors synergize to induce senescence in cancers with an intact G1/S checkpoint. , 2017, , . | | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 145 | Abstract A15: Downregulation of c-myc is synthetic lethal with PARP inhibitors in high MYC cancers independent of BRCA status. , 2017, , . | | 0 |
| 146 | Abstract 1843: Combination therapy targeting Rb/Wee1 kinase pathways for rhabdomyosarcoma treatment. , 2018, , . | | 0 |
| 147 | Cytoplasmic cyclin E independently predicts recurrence in older patients with primary breast cancer.. Journal of Clinical Oncology, 2019, 37, 3128-3128. | 0.8 | 0 |
| 148 | Abstract P6-04-12: STAT3 as a therapeutic target in estrogen receptor positive breast cancer patients refractory to CDK4/6 inhibition. , 2020, , . | | 0 |
| 149 | Abstract P3-10-02: Neutrophil elastase as a therapeutic target to inhibit metastasis in breast cancer. , 2020, , . | | 0 |
| 150 | Abstract P4-06-03: Assessment of intratumoral heterogeneity in early stage estrogen receptor (ER) positive breast cancer. , 2020, , . | | 0 |
| 151 | Abstract P6-03-09: Role of IL-6 in promoting endocrine therapy and palbociclib resistance estrogen receptor positive breast cancer cells. , 2020, , . | | 0 |
| 152 | Abstract P2-05-02: Low molecular weight cyclin E facilitate replication stress tolerance in breast cancer development. Cancer Research, 2022, 82, P2-05-02-P2-05-02. | 0.4 | 0 |
| 153 | Abstract 323: Combined inhibition of STAT-3 & DNA repair in palbociclib resistant breast cancer. , 2019, , . | | 0 |